Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yacine Maringer
Observed names:
Maringer, Yacine,
Maringer, Yacine Ileana,
Y. Maringer
Institutions:
Universitätsklinikum Tübingen,
University of Tübingen
Observed institutions:
Universitätsklinikum Tübingen,
Deutsches Konsortium für Translationale Krebsforschung,
University of Tübingen
ORCID:
0000-0002-2197-8740
Observed ORCID:
0000-0002-2197-8740
OpenAlex ID:
A5008873049
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
2020
·
Annika Nelde
, Tatjana Bilich
, et al.
·
Nature Immunology
·
628
PDF
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
2021
·
Jonas S. Heitmann
, Tatjana Bilich
, et al.
·
Nature
·
274
PDF
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
2021
·
Tatjana Bilich
, Annika Nelde
, et al.
·
Science Translational Medicine
·
160
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
2022
·
Jens Bauer
, Natalie Köhler
, et al.
·
Nature Communications
·
82
PDF
Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination
2022
·
Yacine Maringer
, Annika Nelde
, et al.
·
Science Immunology
·
72
A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes
2021
·
Eva Haas
, Rana D. Incebacak
, et al.
·
Molecular Neurobiology
·
54
PDF
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
2021
·
Tatjana Bilich
, Malte Roerden
, et al.
·
Cancer Discovery
·
44
PDF
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia
2021
·
Annika Nelde
, Yacine Maringer
, et al.
·
Frontiers in Immunology
·
41
PDF
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
2023
·
Jonas S. Heitmann
, Claudia Tandler
, et al.
·
Nature Communications
·
38
PDF
Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells
2023
·
Annika Nelde
, Heiko Schuster
, et al.
·
Blood Cancer Discovery
·
35
PDF
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
2024
·
Christopher Hackenbruch
, Jens Bauer
, et al.
·
Frontiers in Oncology
·
23
PDF
Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants
2022
·
Daniel Junker
, Matthias Becker
, et al.
·
Clinical Infectious Diseases
·
19
PDF
Landscape of T‐cell repertoires with public COVID‐19‐associated T‐cell receptors in pre‐pandemic risk cohorts
2021
·
Donjete Simnica
, Christoph Schultheiß
, et al.
·
Clinical & Translational Immunology
·
19
PDF
Calpain-1 ablation partially rescues disease-associated hallmarks in models of Machado-Joseph disease
2020
·
Jonasz J Weber
, Eva Haas
, et al.
·
Human Molecular Genetics
·
19
PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
2025
·
Steffen Lemke
, Marissa L Dubbelaar
, et al.
·
Journal for ImmunoTherapy of Cancer
·
17
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults
2023
·
Claudia Tandler
, Jonas S. Heitmann
, et al.
·
International Journal of Infectious Diseases
·
16
PDF
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients
2024
·
Susanne Jung
, Annika Nelde
, et al.
·
Frontiers in Oncology
·
11
PDF
Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort
2022
·
Christian M. Tegeler
, Tatjana Bilich
, et al.
·
International Journal of Infectious Diseases
·
11
PDF
Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome
2023
·
Christopher Hackenbruch
, Yacine Maringer
, et al.
·
Viruses
·
9
PDF
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens
2024
·
Alexander Englisch
, Clara Hayn
, et al.
·
Frontiers in Oncology
·
8
PDF
Tumorvakzinierung –Strategien und Timing
2021
·
Yacine Maringer
, Juliane S. Walz
·
Der Internist
·
7
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients
2024
·
Jonas S. Heitmann
, Susanne Jung
, et al.
·
Frontiers in Immunology
·
5
PDF
Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome
2022
·
Maddalena Marconato
, Yacine Maringer
, et al.
·
Cancers
·
5
PDF
Abstract CT258: Interim safety and immunogenicity results of a phase I trial evaluating the multi-peptide COVID-19 vaccine candidate CoVac-1 for induction of SARS-CoV-2 T cell immunity in cancer patients with disease- or treatment-related immunoglobulin deficiency
2022
·
Claudia Tandler
, Jonas S. Heitmann
, et al.
·
Cancer Research
·
4
Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study
2026
·
Jonas S Heitmann
, Yacine Maringer
, et al.
·
The Lancet Haematology
·
2
Show more works
View as search
Works count:
55
Citation count:
1,617
H-index:
16
I10-index:
18
Year
Topic
Type